RARE

#1847
Ultragenyx Pharmaceutical Inc.
24.66 USD
+4.36%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
24.44
24.68
Годовой диапазон
18.29
42.37
Дневное изменение
+4.36%
Месячное изменение
+14.33%
6-месячное изменение
-22.38%
Годовое изменение
-29.46%
Предыдущее закрытие
23.63
Открыть
24.51
Bid
Ask
Минимум
24.44
High
24.68
Объем
348
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 2.38 B
  • Employee 1 371
  • Founded 2010
  • CEO Emil Kakkis
  • Website www.ultragenyx.com
  • Headquarter Delaware, United States
  • FIGI BBG001RWPDW6
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-3.95
Коэффициент цена/денежный поток
3.37

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA.

Новости